Given the results observed in the CheckMate 816 trial, nivolumab gained EMA approval as a neoadjuvant treatment in combination with chemotherapy in patients with resectable NSCLC and PD-L1 expression ≥ 1%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.